How Syngene’s ‘first-time right’ process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully
Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.